Aryl or heteroaryl substituted glutarimide derivatives and their use
CN119768392APending Publication Date: 2025-04-04GLUETACS THERAPEUTICS (SHANGHAI) CO LTD
0 Cites 0 Cited by
Patent Information
- Application Number
- CN202480001712.7
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Priority Date
- 2023-08-03
- Filing Date
- 2024-08-02
- Publication Date
- 2025-04-04
AI Technical Summary
Technical Problem
Existing molecular glue degraders have limited structural novelty and are difficult to meet the need for diversified framework design and development of more molecular glues, especially in the treatment of diseases associated with cereblon protein.
Method used
A series of molecular colloidal protein degradation drugs based on aryl or heteroaryl substituted glutarimide backbones were designed and developed to achieve protein degradation by binding to cereblon and recruiting substrate proteins.
Benefits of technology
These new molecular gel drugs can effectively degrade target proteins, exhibit pharmacological effects such as anti-tumor and immunomodulation, and provide new therapeutic strategies, especially for diseases related to cereblon.
✦ Generated by Eureka AI based on patent content.
Abstract
The present disclosure relates to a compound of formula (I) or a salt thereof, an enantiomer, a stereoisomer, a solvate, an isotope-enriched analog, a prodrug or a polymorph thereof and its use. The present disclosure also relates to a pharmaceutical composition comprising a compound of formula (I) or a salt thereof, an enantiomer, a stereoisomer, a solvate, an isotope-enriched analog, a prodrug or a polymorph thereof as an active ingredient and its use. A series of compounds designed and synthesized by the present disclosure can effectively prevent or treat diseases or conditions associated with cereblon protein, including tumors or cancer. #imgabs0#
Need to check novelty before this filing date? Find Prior Art